Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 9/20 | 0.54 |
| ▸ | THRA | P10827 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15112593 | 0.84 | THRB (0.76) | THRBTHRAMEN1KMT2A | |
| SCHEMBL15494202 | 0.81 | THRB (0.48) | THRBTHRAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3658063 | 0.80 | THRB (0.47) | THRBTHRAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3656867 | 0.79 | HSD11B1 (0.39) | THRBSMN1; SMN2GAACNR2P2RX3 | |
| SCHEMBL3655824 | 0.79 | P2RX3 (0.39) | THRBTHRASMN1; SMN2GAACNR2 | |
| SCHEMBL137173 | 0.78 | ABL1 (0.43) | THRBTHRAKMT2AGAACNR2 | |
| SCHEMBL3659832 | 0.77 | APP (0.58) | THRBKDM4E | |
| SCHEMBL4887024 | 0.76 | THRB (0.86) | THRBTHRA | |
| SCHEMBL3654259 | 0.76 | THRA (0.40) | THRBTHRAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3655417 | 0.75 | THRB (0.45) | THRBTHRASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234954-B1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS INC (US) | 2015-02-18 | — | — | EP | disclosed |
| EP-2234954-B1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS INC (US) | 2015-02-18 | — | — | EP | disclosed |
| US-20140364641-A1 | Tetrasubstituted Benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364641-A1 | Tetrasubstituted Benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364641-A1 | Tetrasubstituted Benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8664249-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664249-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664249-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| WO-2013106328-A1 | TETRASUBSTITUTED BENZENES FOR TREATMENT OF EARLY ONSET ALZHEIMER'S DISEASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20130165486-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8217064-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217064-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217064-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| CN-101945848-A | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS INC | 2011-01-12 | — | — | CN | disclosed |
| EP-2234954-A1 | TETRASUBSTITUTED BENZENES | Envivo Pharmaceuticals, Inc. (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20090299072-A1 | Tetrasubstituted Benzenes | EN VIVO PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090299072-A1 | Tetrasubstituted Benzenes | EN VIVO PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090299072-A1 | Tetrasubstituted Benzenes | EN VIVO PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| WO-2009086277-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086277-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364641-A1 | Tetrasubstituted Benzenes | BACE1, BACE2, PSEN1 | THRB 833/4885THRA 2771/4885MEN1 4444/4885 |
| US-20090299072-A1 | Tetrasubstituted Benzenes | BACE1, BACE2, PSEN1 | THRB 833/4885THRA 2771/4885MEN1 4444/4885 |
| US-20130165486-A1 | TETRASUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | THRB 833/4885THRA 2771/4885MEN1 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.